ArticleFrontiers in cardiovascular medicine2023

Regional differences in physicians' behavior and factors influencing the intensity of PCSK9 inhibitor therapy with alirocumab: a subanalysis of the ODYSSEY APPRISE study.

Maciej Banach et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.